Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
ID: 357307Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357307

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-248.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research" through Cooperative Agreements (U01). This initiative aims to advance research in cancer etiology and early detection biomarkers by utilizing the unique biorepository resources from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, which includes pre-diagnostic blood samples and associated clinical data. The research projects must specifically involve PLCO biospecimens and focus on exploring cancer risk factors and early detection biomarkers, with the overarching goal of reducing cancer risk and improving the quality of life for survivors. Interested applicants can find more information and submit their proposals by the closing date of October 8, 2027, and should direct inquiries to grantsinfo@nih.gov for further assistance.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-248-Full-Announcement.html
    PAR-25-248.html
    The National Cancer Institute (NCI) is announcing a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research" through Cooperative Agreements (U01). This funding aims to advance research utilizing the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial's biorepository, which contains pre-diagnostic blood samples and associated clinical data. Projects must involve PLCO biospecimens to explore cancer risk factors, early detection biomarkers, and potential non-cancer outcomes related to aging. The overarching goal is to reduce cancer risk and improve survivors' quality of life, with applications encouraged from diverse organizations. The funding spans several deadlines starting from January 10, 2025, and allows up to five years for projects. Eligible applicants must navigate specific application requirements, including obtaining specimen verification and adhering to NIH policies. Overall, this funding opportunity emphasizes innovative research into the use of unique biospecimens to address critical questions in cancer detection and prevention, reflecting federal priorities in public health.
    Similar Opportunities
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.
    Forecast to Publish a Funding Opportunity Announcement for Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for research in cancer epidemiology cohort studies through a Cooperative Agreement. This initiative aims to support hypothesis-based research that addresses critical knowledge gaps in cancer etiology and survivorship, including the maintenance of cohorts, continued follow-up, and the sharing of data and biospecimen resources. This funding is vital for advancing understanding in the field of cancer research, which can lead to improved outcomes for patients. Interested small businesses can reach out to Dr. Somdat Mahabir at mahabir@mail.nih.gov or call 240-276-6914 for more information. The estimated synopsis post date is August 1, 2025, with applications due by November 5, 2025, and awards expected to be made by July 1, 2026.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Forecast to Publish a Funding Opportunity Announcement for Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of cancer epidemiology cohorts through the "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" initiative. This cooperative agreement aims to address critical knowledge gaps in cancer etiology and survivorship by laying the groundwork for future studies that will explore various factors influencing cancer risk and outcomes. Eligible applicants for this discretionary grant include small businesses, with no cost-sharing or matching requirements. Interested parties should note that the estimated synopsis post date is August 1, 2025, and applications are due by November 5, 2025, with awards expected to be made by July 1, 2026. For further inquiries, contact Naoko Ishibe Simonds, Sc.D., or Lisa Gallicchio, Ph.D., at 240-276-6967 or via email at naoko.simonds@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer" through a cooperative agreement mechanism (UH2/UH3). This initiative aims to support the validation of molecular, cellular, and imaging biomarkers essential for cancer detection, diagnosis, prognosis, and treatment response monitoring, with a focus on both analytical and clinical validation phases. The funding is intended for projects that demonstrate a working assay on human samples and justify its clinical relevance, fostering multi-disciplinary collaborations among scientific investigators, oncologists, and clinical laboratory scientists. Interested applicants should note that the application deadline is October 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant to enhance cancer screening and preventive services for populations experiencing health disparities. This initiative aims to address barriers to cancer care by developing interventions that operate at multiple levels, including patient, clinician, healthcare settings, and community factors, while encouraging collaboration with community partners. The funding reflects NIH's commitment to advancing health equity, particularly for historically underserved groups, and requires applicants to submit a Plan for Enhancing Diverse Perspectives. Interested applicants can find more information and guidelines at the provided link, with applications due by January 7, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infections with multiple pathogens, excluding HIV. This initiative seeks to investigate the mechanisms and epidemiology of cancer linked to various infectious agents, addressing significant gaps in the current understanding of cancer etiology, with a focus on health disparities in underrepresented populations. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and foreign organizations, with no budget limit for applications, although strong preliminary data is required. Key deadlines include an earliest submission date of January 5, 2025, and a close date of January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html.